JY09
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
1
Countries
1
Endpoints
0
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04354090Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09 | JY09 Type 2 diabetes | BMI 18-26 | Ph 1 | Completed | 1 | Dec 2018 | - |
Showing 1-1 of 1 trials